NF2 antibody | knockout validation | Abcam ab109244

This is a knockout-validated antibody summary, based on the publications "Genome-scale CRISPR-Cas9 knockout screening in human cells", as cited below [1] and "Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer" for western blot knockout validation (figure s5h, s5k) [2]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Rabbit monoclonal IgG

Company: Abcam

Antibody: NF2

Catalog number: ab109244

Summary: Rabbit monoclonal IgG against a synthetic peptide corresponding to the C-terminus of human NF2/Merlin. Reacts with human, mouse, rat. Suitable for western blot and immunoprecipitation.

Validation Method

Western blot

Sample

Control and NF2-KO (lentiCRISPR-infected) A375 cells. Cells were lysed in Cell Lysis Buffer (Cell Signaling 9803) with protease inhibitors (Sigma P8340).

Primary incubation

1:1,000 dilution.

Detection

Membranes were developed by SuperSignal West Femto ECL (Thermo/Pierce) and imaged using BioRad ChemiDoc MP imaging system.

Figure

Please see Figure 4d in the article [1].

References
  1. Shalem O, Sanjana N, Hartenian E, Shi X, Scott D, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84-87 pubmed publisher
  2. Vichas A, Riley A, Nkinsi N, Kamlapurkar S, Parrish P, Lo A, et al. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. Nat Commun. 2021;12:4789 pubmed publisher